Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Allovir Inc (NQ: ALVR )

4.155 -0.725 (-14.86%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 226,302
Open 4.860
Bid (Size) 3.960 (1)
Ask (Size) 4.360 (1)
Prev. Close 4.880
Today's Range 4.154 - 4.860
52wk Range 3.170 - 10.29
Shares Outstanding 93,463,200
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
AlloVir Appoints Derek Adams, Ph.D., to Board of Directors
From AlloVir
Via Business Wire

Performance

YTD
-20.55%
-20.55%
1 Month
-34.98%
-34.98%
3 Month
-27.23%
-27.23%
6 Month
-47.41%
-47.41%
1 Year
-45.26%
-45.26%

More News

Read More
AlloVir Announces Final Results From Posoleucel Study In Kidney Transplant Recipients With BK Viremia, Shares Fall
Via Benzinga
AlloVir Reports Full-Year 2022 Financial Results and 2023 Outlook
From AlloVir, Inc.
Via Business Wire
Recap: AlloVir Q2 Earnings
Via Benzinga
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia
From AlloVir, Inc.
Via Business Wire
AlloVir to Participate in the SVB Securities Global Biopharma Conference
From AlloVir, Inc.
Via Business Wire
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023
From AlloVir, Inc.
Via Business Wire
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference
From AlloVir, Inc.
Via Business Wire
AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition
From AlloVir
Via Business Wire
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference
From AlloVir
Via Business Wire
AlloVir: Q3 Earnings Insights
Via Benzinga
Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting
From AlloVir, Inc.
Via Business Wire
AlloVir Reports Third Quarter 2022 Financial Results
From AlloVir, Inc.
Via Business Wire
Moderna, Zscaler And This Biotechnology Stock Insiders Are Selling
Via Benzinga
Why Super Micro Computer Shares Jumped Over 10%; Here Are 73 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
From AlloVir, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
AlloVir Reports Second Quarter 2022 Financial Results
From AlloVir, Inc.
Via Business Wire
Why FlexShopper Surged Over 47%; Here Are 104 Biggest Movers From Yesterday
Via Benzinga
Why Matterport Is Trading Higher By Around 25%, Here Are 73 Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
Via Benzinga
Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Why Shares Of Cannabis Companies Traded Higher; Here Are 101 Biggest Movers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.